The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough (CACTUS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jan W.K. van den Berg, Isala Klinieken
ClinicalTrials.gov Identifier:
NCT01071161
First received: February 17, 2010
Last updated: April 5, 2013
Last verified: April 2013

February 17, 2010
April 5, 2013
September 2009
February 2012   (final data collection date for primary outcome measure)
Mean change in the Leicester Cough Questionnaire (LCQ) scores. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01071161 on ClinicalTrials.gov Archive Site
  • Mean change in the SF 36 and SGRQ scores. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Change in lung function, (FEV1 (L) and FVC (L)). [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Number of exacerbations. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Adverse reactions. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Laboratory values: CRP, ASAT, ALAT [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Sputum analysis [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough
Phase III (c) The Effect of Azithromycin in Patients With COPD and Chronic Productive Cough

The purpose of this study is to demonstrate the efficacy of azithromycin to produce a significant change in the cough-related health status, measured with the Dutch version of the Leicester Cough Questionnaire in patiënts with COPD gold classification 2-4 and chronic productive coughing.

This study is a prospective double-centre, double blind randomised trial. Patients > 40 years of age, referred to our outpatient clinic with chronic cough and sputum production due to COPD will be recruited after informed consent is obtained.

Consenting patients will be randomises to a 12-week treatment with 250 mg azithromycin three times a week or placebo.

Before randomisation all patients have to fill in the SF 36 , SGRQ and the Dutch version of the Leicester Cough Questionnaire (LCQ) for assessment of the baseline quality of life and the disease specific quality of life.

The LCQ questionnaires will be performed at the beginning and every 3 weeks afterwards until 18 weeks, except the second LCQ which will be filled in after 2 weeks. Scores from this questionnaire will be used to calculate the 2-week repeatability. The SF 36 and SGRQ will be performed at the start of the study and after 12 weeks. Adverse events will be recorded during the whole treatment period. After 2 and 12 weeks a Global Rating of Change will be performed. This questionnaire will be used to validate the LCQ in COPD patients.

Randomisation will take place using a computer allocation program (BAMI-computer)

Azithromycin and placebo will be provided by Teva Pharmaceuticals. Placebo and azithromycin will be identical in appearance and packaging.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Cough
  • Chronic Obstructive Pulmonary Disease
  • Chronic Bronchitis
  • Drug: azithromycin
    azithromycin, tablets, during 12 weeks, three times a week, 250mg
    Other Name: Zithromax
  • Drug: placebo
    placebo
  • Experimental: Azithromycin
    Intervention: Drug: azithromycin
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
February 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients > 40 years of age, in our outpatient clinic with chronic cough and COPD (gold2-4)
  • Chronic cough is defined as a cough > 12 weeks duration, at least 12 weeks a year in 2 subsequent years.
  • Analysed for bronchiectasis prior to participation by CT-thorax.

Exclusion Criteria:

  • Prior history of asthma
  • Use of i.v. or oral corticosteroids and or antibiotics for an exacerbation 3 weeks before inclusion
  • Patients suffering from other relevant lung diseases.
  • Clinically relevant abnormal laboratory values suggesting an unknown disease requiring further clinical evaluation.
  • Liver disease, (ALAT and/or ASAT levels two or more times the upper limit of normal).
  • Pregnancy or lactation.
  • Use of macrolides the last 6 weeks prior to inclusion.
  • Allergy or intolerance to macrolides.
  • Other research medication started 2 months prior to inclusion.
  • Prior randomisation in this study.
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01071161
NL19886.075.08
Yes
Jan W.K. van den Berg, Isala Klinieken
Isala Klinieken
Not Provided
Study Director: Jan Willem van den Berg, MD Department of Pulmonology
Isala Klinieken
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP